Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 22 June 2018, 10:58 HKT/SGT
Share:
    

Source: Eisai
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN)

TOKYO, June 22, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for the first time for membership in the MSCI Japan Empowering Women Index (WIN), an index developed for environmental, social and governance (ESG) investment. This index is one of the indices adopted by the Government Pension Investment Fund (GPIF) for selecting investments based on ESG initiatives as an indicator of non-financial value.

The MSCI Japan Empowering Women Index (WIN) is developed by MSCI Inc., the industry leader in ESG research who offers various tools to support the investment decisions of major investors around the world. For the MSCI Japan Empowering Women Index, MSCI selects industry leading companies in terms of attracting, retaining and promoting women, as well as advancing gender diversity. Selection is based on data regarding female employment disclosed according to the Act on Promotion of Women's Participation and Advancement in the Workplace as well as information publicly disclosed by companies such as company policy on gender diversity. In 2012, Eisai issued the Eisai Diversity Declaration, and implements various initiatives aimed at developing an organizational climate for utilizing diverse values as well as promoting the advancement of women.

Eisai has also been selected for inclusion in the FTSE Blossom Japan Index as well as the MSCI Japan ESG Select Leaders Index, which now means that Eisai has been selected for all three ESG indices for Japanese stocks adopted by the GPIF.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this corporate philosophy.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Media Inquiries: 
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


June 22, 2018 10:58 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 14, 2018 12:30 HKT/SGT
Eisai Receives "IR Grand Prix Award"
Nov 12, 2018 11:51 HKT/SGT
Eisai Launches Lenvima (Lenvatinib) in China
Nov 9, 2018 08:08 HKT/SGT
Eisai: New Data from Investigational Study of Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
Nov 8, 2018 14:38 HKT/SGT
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn's Disease Concluded, Research Activities Commence
Nov 8, 2018 08:43 HKT/SGT
Eisai Commences Full-Scale Operation of New Suzhou Plant in China
Oct 29, 2018 08:45 HKT/SGT
Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD
Oct 26, 2018 08:32 HKT/SGT
Eisai Presents New Data on Lemborexant for Treatment of Irregular Sleep-Wake Rhythm Disorder in Patients With Alzheimer's Disease
Oct 26, 2018 07:03 HKT/SGT
Eisai and Biogen Announce Presentation of Additional Data from Phase II Clinical Trial of BAN2401 in Early Alzheimer's Disease
Oct 25, 2018 08:05 HKT/SGT
Eisai to Present Latest Data on Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination and Exploratory Research
Oct 23, 2018 14:13 HKT/SGT
Eisai: Application Seeking Manufacturing and Marketing Approval in Japan Submitted for Parkinson's Disease Treatment Safinamide
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: